MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

Search

Corvus Pharmaceuticals Inc

Geschlossen

3.31 2.8

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.18

Max

3.32

Schlüsselkennzahlen

By Trading Economics

Einkommen

28M

-12M

EPS

-0.143

Angestellte

31

EBITDA

-851K

-8.1M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+290.39% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-52M

221M

Vorheriger Eröffnungskurs

0.51

Vorheriger Schlusskurs

3.31

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Apr. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Union Says Nippon Steel Can't Be Trusted With Buying U.S. Steel

22. Apr. 2025, 20:55 UTC

Ergebnisse

Intuitive Surgical Reports Higher 1Q Profit, Warns of Tariff Hit to Margins

22. Apr. 2025, 23:49 UTC

Market Talk

Nikkei May Rise After Wall Street Rally -- Market Talk

22. Apr. 2025, 23:49 UTC

Market Talk

Gold Falls on Signs of Easing U.S.-China Tensions, Possible Profit-Taking -- Market Talk

22. Apr. 2025, 23:47 UTC

Top News

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 4th Update

22. Apr. 2025, 23:08 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: No Change to Annual Guidance

22. Apr. 2025, 23:07 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Assessing Impacts of Recent Tariff Announcements on Louisiana LNG

22. Apr. 2025, 23:07 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Advancing Talks Targeting Further Equity Selldown in Louisiana LNG

22. Apr. 2025, 23:06 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Trion Project 26% Complete, on Track for First Oil in 2028

22. Apr. 2025, 23:05 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Scarborough Energy Project on Track for First LNG Cargo in 2H 2026

22. Apr. 2025, 23:05 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy: Scarborough Energy Project 82% Complete

22. Apr. 2025, 23:05 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy: Beaumont New Ammonia Project on Track to Start in 2H

22. Apr. 2025, 23:05 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy: Beaumont New Ammonia Project 90% Complete

22. Apr. 2025, 23:04 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy: Share of Sangomar Production Maintained at 78 Million Bbl/Day in 1Q

22. Apr. 2025, 23:04 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Macquarie Set for A$500 Million Gain on Sale From Nomura Deal -- Market Talk

22. Apr. 2025, 23:04 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Sold 25.4% of Produced LNG at Prices Linked to Gas Hub Indices in 1Q

22. Apr. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Cites Lower Output, Reduced Oil-Linked Prices for Revenue Fall

22. Apr. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy 1Q Revenue Down 5% on Prior Quarter

22. Apr. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy 1Q Revenue US$3.315 Billion

22. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Cites Weather Impacts at North West Shelf, Pluto Unplanned Outages in 1Q

22. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy 1Q Oil, Natural Gas Output Down 4% on Prior Quarter

22. Apr. 2025, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy 1Q Oil, Natural Gas Output 49.1 Million BOE

22. Apr. 2025, 22:31 UTC

Ergebnisse

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- Update

22. Apr. 2025, 22:26 UTC

Top News

Trump Is Laying the Groundwork to Blame Powell for Any Downturn -- Update

22. Apr. 2025, 22:16 UTC

Top News

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 3rd Update

22. Apr. 2025, 22:16 UTC

Market Talk

Turkey Remains on Course for Steadily Lower Inflation, Finance Minister Says -- Market Talk

22. Apr. 2025, 22:04 UTC

Top News

China Tariffs 'Won't Be Anywhere Near' 145%: Trump -- Barrons.com

22. Apr. 2025, 21:42 UTC

Ergebnisse

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- WSJ

22. Apr. 2025, 21:21 UTC

Top News
Ergebnisse

Tesla Profit Sinks, Hurt by Political Backlash -- 3rd Update

22. Apr. 2025, 21:19 UTC

Top News

Investors Hope for No Surprises as Boeing Reports Earnings -- Barrons.com

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

290.39% Vorteil

12-Monats-Prognose

Durchschnitt 13 USD  290.39%

Hoch 15 USD

Tief 11 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

3.32 / 3.365Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.